HUTCHMED (00013) will release key phase II trial data on fruquintinib for the treatment of intrahepatic cholangiocarcinoma at the 2026 European Society for Medical Oncology Congress on Gastrointestinal Oncology.

HUTCHMED (00013) announced that the results of a pivotal Phase II registration study of surufatinib (HMPL-453) for the treatment of patients with intrahepatic cholangiocarcinoma will be presented at the European Society of Medical Oncology (ESMO) GI Cancer Congress in Munich, Germany from July 1 to July 4, 2026. Based on the data from this study, a new drug application for surufatinib for the treatment of adults with advanced, metastatic, or unresectable intrahepatic cholangiocarcinoma who have previously received systemic therapy and have fibroblast growth factor receptor (FGFR) 2 fusion or rearrangement was accepted by the China National Medical Products Administration in December 2025 and granted priority review. Professor Xu Jianming from the Chinese People's Liberation Army General Hospital, the lead investigator of the study, stated, "For patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusion/rearrangement, there remains a significant unmet need for effective clinical treatment. All participants in the study had disease progression after prior chemotherapy, with the majority also having received immunotherapy. The results of this registration clinical study represent an important milestone in the field of targeted therapy for FGFR2 aberrant intrahepatic cholangiocarcinoma. The objective response rate and survival outcomes demonstrated by surufatinib strongly support its clinical value as a highly effective and selective oral treatment option. We are encouraged by these results and look forward to the swift translation of this innovative therapy into clinical practice to address critical unmet clinical needs in the field of digestive tract tumors."